Compare Equinor ASA (EQNR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs GeneDx Holdings Corp — how do they compare? Equinor ASA trades at $43.01 (market cap $101.62B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Equinor ASA is far larger — about 50.3× GeneDx Holdings Corp's market cap, and Equinor ASA pays a 3.63% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and GeneDx Holdings Corp for 19 Days on average.
| EQNR | WGS | |
|---|---|---|
Market Cap | $101.62B | $2.02B |
Volume | 4,991,782 | 734,640 |
Sector | Energy | Health |
52-Week High | $45.75 | $167.51 |
52-Week Low | $22.41 | $34.51 |
Typical Hold Time | 59 Days | 19 Days |
Enterprise Value | $110.31B | $2.05B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $42.93, up 3.17% today, with a bullish technical outlook supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 2.39, while maintaining strong profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues expanding its LNG portfolio with new Asian supply agreements.
EQNR presents compelling value with significant upside to the $87.50 consensus price target. However, declining revenue and net income margins since 2022, coupled with negative net cash flow trends, warrant caution. The stock's performance remains sensitive to energy market volatility and execution of LNG expansion plans through the early 2030s.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
